D-0251-2026 Class II Ongoing

Recalled by Imprimis NJOF, LLC — Ledgewood, NJ

FDA drug recall D-0251-2026 was initiated by Imprimis NJOF, LLC on Dec 18, 2025 and is designated Class II. Reason for recall: Presence of particulate matter - Glass like particles. The recall status is ongoing. Affected quantity: 314 boxes of 6,280 pre-filled syringes.

Recall details

Product Type
Drugs
Report Date
Jan 14, 2026
Initiation Date
Dec 18, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
314 boxes of 6,280 pre-filled syringes

Product description

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.

Reason for recall

Presence of particulate matter - Glass like particles.

Distribution pattern

U.S Nationwide

Code information

Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0251-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0251-2026. Report a data issue: hello@regdatalab.com.